The expression of mRNA for a kappa opioid receptor in the substantia nigra of Parkinson's disease brain. 1997

M Yamada, and K Groshan, and C T Phung, and M Yamada, and T Hisamitsu, and E Richelson
Department of Psychiatry, Mayo Foundation and Mayo Clinic Jacksonville, FL 32224, USA.

We molecularly cloned the kappa opioid receptor from a human substantia nigra cDNA library. When expressed in HEK293 cells, the cloned receptor had similar pharmacological characteristics to the rat kappa opioid receptor. Northern blot analysis showed the presence of a single transcript of about 6 kb in size for mRNA prepared from the substantia nigra. Using in situ hybridization histochemistry, we studied the expression of this receptor in postmortem human brains from control and Parkinson's disease subjects. Kappa opioid receptor mRNA was present in melanized (possibly dopaminergic) neurons of the substantia nigra and the nucleus paranigralis. On the other hand, Parkinson's disease brains had markedly fewer melanized neurons, as expected, and correspondingly very low or background levels of mRNA for the kappa opioid receptor. However, in some cases, remaining melanized neurons still expressed the receptor mRNA. From these results we suggest that dopaminergic neurons in the human substantia nigra and the nucleus paranigralis synthesize kappa opioid receptors and express them in their perikarya and their terminal regions. The kappa opioid receptor expressed in the melanized neurons may play a role in the normal function of dopaminergic systems and possibly in the etiology of Parkinson's disease.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010300 Parkinson Disease A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75) Idiopathic Parkinson Disease,Lewy Body Parkinson Disease,Paralysis Agitans,Primary Parkinsonism,Idiopathic Parkinson's Disease,Lewy Body Parkinson's Disease,Parkinson Disease, Idiopathic,Parkinson's Disease,Parkinson's Disease, Idiopathic,Parkinson's Disease, Lewy Body,Parkinsonism, Primary
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D000369 Aged, 80 and over Persons 80 years of age and older. Oldest Old
D012333 RNA, Messenger RNA sequences that serve as templates for protein synthesis. Bacterial mRNAs are generally primary transcripts in that they do not require post-transcriptional processing. Eukaryotic mRNA is synthesized in the nucleus and must be exported to the cytoplasm for translation. Most eukaryotic mRNAs have a sequence of polyadenylic acid at the 3' end, referred to as the poly(A) tail. The function of this tail is not known for certain, but it may play a role in the export of mature mRNA from the nucleus as well as in helping stabilize some mRNA molecules by retarding their degradation in the cytoplasm. Messenger RNA,Messenger RNA, Polyadenylated,Poly(A) Tail,Poly(A)+ RNA,Poly(A)+ mRNA,RNA, Messenger, Polyadenylated,RNA, Polyadenylated,mRNA,mRNA, Non-Polyadenylated,mRNA, Polyadenylated,Non-Polyadenylated mRNA,Poly(A) RNA,Polyadenylated mRNA,Non Polyadenylated mRNA,Polyadenylated Messenger RNA,Polyadenylated RNA,RNA, Polyadenylated Messenger,mRNA, Non Polyadenylated
D013378 Substantia Nigra The black substance in the ventral midbrain or the nucleus of cells containing the black substance. These cells produce DOPAMINE, an important neurotransmitter in regulation of the sensorimotor system and mood. The dark colored MELANIN is a by-product of dopamine synthesis. Nigra, Substantia,Nigras, Substantia,Substantia Nigras
D017403 In Situ Hybridization A technique that localizes specific nucleic acid sequences within intact chromosomes, eukaryotic cells, or bacterial cells through the use of specific nucleic acid-labeled probes. Hybridization in Situ,Hybridization, In Situ,Hybridizations, In Situ,In Situ Hybridizations

Related Publications

M Yamada, and K Groshan, and C T Phung, and M Yamada, and T Hisamitsu, and E Richelson
February 1996, Neuroscience letters,
M Yamada, and K Groshan, and C T Phung, and M Yamada, and T Hisamitsu, and E Richelson
November 2000, Experimental neurology,
M Yamada, and K Groshan, and C T Phung, and M Yamada, and T Hisamitsu, and E Richelson
February 2013, Neural regeneration research,
M Yamada, and K Groshan, and C T Phung, and M Yamada, and T Hisamitsu, and E Richelson
February 1999, Neuroreport,
M Yamada, and K Groshan, and C T Phung, and M Yamada, and T Hisamitsu, and E Richelson
March 2001, Neuroscience letters,
M Yamada, and K Groshan, and C T Phung, and M Yamada, and T Hisamitsu, and E Richelson
December 2010, Acta neurochirurgica,
M Yamada, and K Groshan, and C T Phung, and M Yamada, and T Hisamitsu, and E Richelson
March 1993, The Journal of comparative neurology,
M Yamada, and K Groshan, and C T Phung, and M Yamada, and T Hisamitsu, and E Richelson
April 2007, Neurogenetics,
M Yamada, and K Groshan, and C T Phung, and M Yamada, and T Hisamitsu, and E Richelson
April 2007, Journal of neuroimaging : official journal of the American Society of Neuroimaging,
M Yamada, and K Groshan, and C T Phung, and M Yamada, and T Hisamitsu, and E Richelson
May 1999, Movement disorders : official journal of the Movement Disorder Society,
Copied contents to your clipboard!